| Date Filed | Type | Description |
| 10/03/2023 |
4
| Mertens Steve (Chief Technology Officer) has filed a Form 4 on NEUROONE MEDICAL TECHNOLOGIES Corp|
Txns:
| Paid exercise price by delivering 252 shares
@ $0.8904, valued at
$224.4 |
|
| 10/03/2023 |
4
| Christianson Mark (Business Development Director) has filed a Form 4 on NEUROONE MEDICAL TECHNOLOGIES Corp|
Txns:
| Paid exercise price by delivering 90 shares
@ $0.8904, valued at
$80.1 |
|
| 10/03/2023 |
4
| Rosa David A (CEO and President) has filed a Form 4 on NEUROONE MEDICAL TECHNOLOGIES Corp|
Txns:
| Paid exercise price by delivering 2,239 shares
@ $0.8904, valued at
$2k
|
|
| 08/14/2023 |
8-K
| Quarterly results|
Docs:
|
"NeuroOne Medical Technologies Corporation Condensed Balance Sheets June 30, 2023 September 30, 2022 Assets Current assets: Cash and cash equivalents $ 3,083,458 $ 8,160,329 Short-term investments — 2,981,010 Accounts receivable — 33,237 Inventory 1,516,527 704,538 Prepaids and other 278,786 296,649 Total current assets 4,878,771 12,175,763 Intangible assets, net 95,156 111,892 Right-of-use asset 197,324 181,355 Property and equipment, net 586,873 353,599 Total assets $ 5,758,124 $ 12,822,609 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 958,811 $ 927,662 Accrued expenses and other liabilities 789,097 715,839 Deferred revenue — 1,455,188 Total current liabilities 1,747,908 3,098,689 Operating lease liability, long term 88,918 119,556 Total liabilities 1,836,82..." |
|
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/01/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/27/2023 |
8-K
| Asset disposition |
| 07/26/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 07/24/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 07/24/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 07/05/2023 |
4
| Mertens Steve (Chief Technology Officer) has filed a Form 4 on NEUROONE MEDICAL TECHNOLOGIES Corp|
Txns:
| Paid exercise price by delivering 252 shares
@ $1.2, valued at
$302.4 |
|
| 07/05/2023 |
4
| Christianson Mark (Business Development Director) has filed a Form 4 on NEUROONE MEDICAL TECHNOLOGIES Corp|
Txns:
| Paid exercise price by delivering 90 shares
@ $1.2, valued at
$108 |
|
| 07/05/2023 |
4
| Rosa David A (CEO and President) has filed a Form 4 on NEUROONE MEDICAL TECHNOLOGIES Corp|
Txns:
| Paid exercise price by delivering 2,239 shares
@ $1.2, valued at
$2.7k
|
|
| 06/01/2023 |
4
| Mertens Steve (Chief Technology Officer) has filed a Form 4 on NEUROONE MEDICAL TECHNOLOGIES Corp|
Txns:
| Paid exercise price by delivering 252 shares
@ $1.21, valued at
$304.9 |
|
| 06/01/2023 |
4
| Christianson Mark (Business Development Director) has filed a Form 4 on NEUROONE MEDICAL TECHNOLOGIES Corp|
Txns:
| Paid exercise price by delivering 90 shares
@ $1.21, valued at
$108.9 |
|
| 06/01/2023 |
4
| Rosa David A (CEO and President) has filed a Form 4 on NEUROONE MEDICAL TECHNOLOGIES Corp|
Txns:
| Paid exercise price by delivering 2,239 shares
@ $1.21, valued at
$2.7k
|
|
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/25/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/25/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/25/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/25/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/04/2023 |
4
| Mertens Steve (Chief Technology Officer) has filed a Form 4 on NEUROONE MEDICAL TECHNOLOGIES Corp|
Txns:
| Paid exercise price by delivering 252 shares
@ $1.61, valued at
$405.7 |
|
| 04/04/2023 |
4
| Christianson Mark (Business Development Director) has filed a Form 4 on NEUROONE MEDICAL TECHNOLOGIES Corp|
Txns:
| Paid exercise price by delivering 90 shares
@ $1.61, valued at
$144.9 |
|
| 04/04/2023 |
4
| Rosa David A (CEO and President) has filed a Form 4 on NEUROONE MEDICAL TECHNOLOGIES Corp|
Txns:
| Paid exercise price by delivering 2,239 shares
@ $1.61, valued at
$3.6k
|
|
| 03/24/2023 |
4
| Christianson Mark (Business Development Director) has filed a Form 4 on NEUROONE MEDICAL TECHNOLOGIES Corp|
Txns:
| Sold 2,122 shares
@ $1.6048, valued at
$3.4k
Sold 11,667 shares
@ $1.5085, valued at
$17.6k
Sold 12,711 shares
@ $1.502, valued at
$19.1k
|
|
| 03/20/2023 |
4
| MATHIESEN JEFFREY S (Director) has filed a Form 4 on NEUROONE MEDICAL TECHNOLOGIES Corp|
Txns:
| Granted 20,576 shares
@ $0
Granted 18,927 options to buy
@ $1.62, valued at
$30.7k
|
|
| 03/20/2023 |
4
| BUCKMAN PAUL (Director) has filed a Form 4 on NEUROONE MEDICAL TECHNOLOGIES Corp|
Txns:
| Granted 20,576 shares
@ $0
Granted 18,927 options to buy
@ $1.62, valued at
$30.7k
|
|
| 03/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/17/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
|